<DOC>
	<DOCNO>NCT00949819</DOCNO>
	<brief_summary>Active Surveillance ( A.S. ) prostate cancer ( CaP ) systematic monitor men low-risk , localized lesion , curative treatment whose tumor show substantial progression . A.S. different Watchful Waiting ( W.W. ) , palliative treatment men progressive prostate cancer .</brief_summary>
	<brief_title>Active Surveillance Cancer Prostate ( ASCaP )</brief_title>
	<detailed_description>This protocol design formal clinical trial , rather observational protocol ; treatment randomization include . Longitudinally , specimens clinical data collect provide information following : - Imaging study prostate - Rates curative intervention - Measures tumor recurrence/progression - Disease specific survival - Overall survival - Clinical data track Quality Life</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma prostate . 2 . Clinically localized prostate cancer : T12 , NX N0 , MX M0 . 3 . No previous treatment prostate cancer ( include hormonal therapy , radiation therapy , surgery , chemotherapy ) . 4 . Patient elect Active Surveillance prefer management plan prostate cancer . 5 . Patient consent obtain accord local Institutional Review Board . 6 . Patient accessible compliant followup . 1 . Unwillingness inability undergo serial prostate biopsy . 2 . Overall life expectancy le 2 year 3 . Advanced prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Low risk</keyword>
	<keyword>Gleason 6</keyword>
	<keyword>Active surveillance</keyword>
</DOC>